India
oi-Ajay Joseph Raj P
New Delhi, Mar 13: Amid concerns over dangerous side-effects of the Oxford’s COVID-19 vaccine, India is evaluating all serious adverse events post-vaccination to determine the causality aspects of Covishield and Covaxin, an expert associated with the process said Saturday.
His comments came in the backdrop of some European countries suspending the Oxford-AstraZeneca COVID-19 vaccine Covishield over fears that it may be causing dangerous blood clots in some people. India has reported 234 adverse events following immunisation (AEFIs), including 71 deaths, for both the vaccines till Friday, said Dr NK Arora, an advisor to the national AEFI committee.
COVID-19 vaccine-induced antibodies less effective against some coronavirus variants
Manufactured in India by the Serum Institute of India (SII), the Oxford vaccine is one of the two vaccines being used in India currently, the…
